Syndax Pharmaceuticals
SNDX
27 hedge funds and large institutions have $126M invested in Syndax Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$27.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.6M |
| 4 |
O
OrbiMed
New York
|
+$9.52M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.42M |
Top Sellers
SNDX Hedge Fund Activity: Q1 2016 in Review
27 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2016, worth a combined $126M.
Buyers outnumbered sellers: 27 funds opened new SNDX positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM Asset Management, opening a new position worth an estimated $27.3M.
- 27 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2016, up from 0 in Q4 2015.
- Funds reported $126M of Syndax Pharmaceuticals stock for Q1 2016.
- 27 funds opened new Syndax Pharmaceuticals positions in Q1 2016 and 0 closed out, a net change of +27 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2016 was MPM Asset Management, an estimated $27.3M added.
Based on aggregated 13F filings for Q1 2016.